https://www.geriatriconcology.net/article/S1879-4068(18)30419-3/fulltext
Authors:
Riaz, F, Presley, CJ, Chiang, AC, Longtine, JA, Soulos, PR, Adelson, KB, Herbst, RS, Nussbaum, NC, Sorg, RA, Abernethy, AP, Agarwala, V, Gross, CP
With technological advancements in the field of precision medicine through broad-based genomic sequencing (BGS), the interrogation of an individual's tumor genome sequence is now possible in the course of routine clinical care. BGS allows for assessments of clinical trial eligibility and potential matching with emerging targeted treatments [
,
]. For this reason, the National Comprehensive Cancer Network (NCCN) guidelines strongly advises BGS in patients with advanced non-small cell lung cancer (aNSCLC) [
].
Sources:
Journal of Geriatric Oncology